MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human arterial hypertension is the most frequent risk factor in the world for cardiovascular disease associated with increased mortality and morbidity. Atrial Natriuretic Peptide (ANP) is a hormone produced by the cardiac atria and has a pivotal role in the regulation of the cardiovascular system and body fluid homeostasis. Its well-known vasomodulatory properties and renin-angiotensin-aldosterone system (RAAS) counteractions, conferred by binding to the Guanylyl Cyclase A Receptor (CG-A) producing the second messenger cyclic GMP) make it a robust therapeutic agent for heart failure and hypertension. Currently, ANP is administered for treatment of HF by continuous intravenous infusion due to short half-life, the main limiting factor for its chronic use. Recently studies have defined a metabolic role of ANP beyond its blood pressure-lowering, natriuretic- and aldosterone-inhibiting properties, such that the ANP gene polymorphism rs5068 is associated with a low cardiovascular risk profile with protection from metabolic syndrome. Further physiological studies established that the gut peptide Glucagon-like Protein 1 (GLP-1) can stimulate the release of ANP from the atria also resulting in cardiorenal protection. Based upon these cardiorenal, humoral and metabolic properties of ANP, we engineered Mutant ANP (MANP) which represents a new and novel ANP-based peptide therapeutic consisting of 40 amino acids where the unique long C-terminus confers to the peptide a greater resistance to degradation than its native form. Indeed, in vitro studies demonstrated fewer sites for degradation and a greater cGMP production than ANP. In vivo studies showed sustained cardiorenal actions with enhanced vasorelaxation not only in normal canines but also in experimental acute hypertension and in hypertensive acute heart failure. In summary, for these reasons, MANP represents a new therapeutic agent for the treatment of chronic and resistant hypertension that is now entering human clinical trials.

Original languageEnglish (US)
Title of host publicationNatriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications
PublisherNova Science Publishers, Inc.
Pages77-100
Number of pages24
ISBN (Print)9781633210837, 9781633210806
StatePublished - Jul 1 2014

Fingerprint

Natriuretic Peptides
Atrial Natriuretic Factor
Treatment Failure
Heart Failure
Hypertension
Peptides
Glucagon-Like Peptides
Therapeutics
Cyclic GMP
Body Fluids
Second Messenger Systems
Renin-Angiotensin System
Cardiovascular System
Aldosterone
Intravenous Infusions
Vasodilation
Half-Life
Canidae
Homeostasis
Cardiovascular Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Puccia, G., Cannone, V., McKie, P., & Burnett, J. C. J. (2014). MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure. In Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications (pp. 77-100). Nova Science Publishers, Inc..

MANP : A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure. / Puccia, Giuseppe; Cannone, Valentina; McKie, Paul; Burnett, John C Jr.

Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications. Nova Science Publishers, Inc., 2014. p. 77-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Puccia, G, Cannone, V, McKie, P & Burnett, JCJ 2014, MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure. in Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications. Nova Science Publishers, Inc., pp. 77-100.
Puccia G, Cannone V, McKie P, Burnett JCJ. MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure. In Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications. Nova Science Publishers, Inc. 2014. p. 77-100
Puccia, Giuseppe ; Cannone, Valentina ; McKie, Paul ; Burnett, John C Jr. / MANP : A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure. Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications. Nova Science Publishers, Inc., 2014. pp. 77-100
@inbook{028cf1ea01fd4cceab3dcec31724e971,
title = "MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure",
abstract = "Human arterial hypertension is the most frequent risk factor in the world for cardiovascular disease associated with increased mortality and morbidity. Atrial Natriuretic Peptide (ANP) is a hormone produced by the cardiac atria and has a pivotal role in the regulation of the cardiovascular system and body fluid homeostasis. Its well-known vasomodulatory properties and renin-angiotensin-aldosterone system (RAAS) counteractions, conferred by binding to the Guanylyl Cyclase A Receptor (CG-A) producing the second messenger cyclic GMP) make it a robust therapeutic agent for heart failure and hypertension. Currently, ANP is administered for treatment of HF by continuous intravenous infusion due to short half-life, the main limiting factor for its chronic use. Recently studies have defined a metabolic role of ANP beyond its blood pressure-lowering, natriuretic- and aldosterone-inhibiting properties, such that the ANP gene polymorphism rs5068 is associated with a low cardiovascular risk profile with protection from metabolic syndrome. Further physiological studies established that the gut peptide Glucagon-like Protein 1 (GLP-1) can stimulate the release of ANP from the atria also resulting in cardiorenal protection. Based upon these cardiorenal, humoral and metabolic properties of ANP, we engineered Mutant ANP (MANP) which represents a new and novel ANP-based peptide therapeutic consisting of 40 amino acids where the unique long C-terminus confers to the peptide a greater resistance to degradation than its native form. Indeed, in vitro studies demonstrated fewer sites for degradation and a greater cGMP production than ANP. In vivo studies showed sustained cardiorenal actions with enhanced vasorelaxation not only in normal canines but also in experimental acute hypertension and in hypertensive acute heart failure. In summary, for these reasons, MANP represents a new therapeutic agent for the treatment of chronic and resistant hypertension that is now entering human clinical trials.",
author = "Giuseppe Puccia and Valentina Cannone and Paul McKie and Burnett, {John C Jr.}",
year = "2014",
month = "7",
day = "1",
language = "English (US)",
isbn = "9781633210837",
pages = "77--100",
booktitle = "Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - MANP

T2 - A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure

AU - Puccia, Giuseppe

AU - Cannone, Valentina

AU - McKie, Paul

AU - Burnett, John C Jr.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Human arterial hypertension is the most frequent risk factor in the world for cardiovascular disease associated with increased mortality and morbidity. Atrial Natriuretic Peptide (ANP) is a hormone produced by the cardiac atria and has a pivotal role in the regulation of the cardiovascular system and body fluid homeostasis. Its well-known vasomodulatory properties and renin-angiotensin-aldosterone system (RAAS) counteractions, conferred by binding to the Guanylyl Cyclase A Receptor (CG-A) producing the second messenger cyclic GMP) make it a robust therapeutic agent for heart failure and hypertension. Currently, ANP is administered for treatment of HF by continuous intravenous infusion due to short half-life, the main limiting factor for its chronic use. Recently studies have defined a metabolic role of ANP beyond its blood pressure-lowering, natriuretic- and aldosterone-inhibiting properties, such that the ANP gene polymorphism rs5068 is associated with a low cardiovascular risk profile with protection from metabolic syndrome. Further physiological studies established that the gut peptide Glucagon-like Protein 1 (GLP-1) can stimulate the release of ANP from the atria also resulting in cardiorenal protection. Based upon these cardiorenal, humoral and metabolic properties of ANP, we engineered Mutant ANP (MANP) which represents a new and novel ANP-based peptide therapeutic consisting of 40 amino acids where the unique long C-terminus confers to the peptide a greater resistance to degradation than its native form. Indeed, in vitro studies demonstrated fewer sites for degradation and a greater cGMP production than ANP. In vivo studies showed sustained cardiorenal actions with enhanced vasorelaxation not only in normal canines but also in experimental acute hypertension and in hypertensive acute heart failure. In summary, for these reasons, MANP represents a new therapeutic agent for the treatment of chronic and resistant hypertension that is now entering human clinical trials.

AB - Human arterial hypertension is the most frequent risk factor in the world for cardiovascular disease associated with increased mortality and morbidity. Atrial Natriuretic Peptide (ANP) is a hormone produced by the cardiac atria and has a pivotal role in the regulation of the cardiovascular system and body fluid homeostasis. Its well-known vasomodulatory properties and renin-angiotensin-aldosterone system (RAAS) counteractions, conferred by binding to the Guanylyl Cyclase A Receptor (CG-A) producing the second messenger cyclic GMP) make it a robust therapeutic agent for heart failure and hypertension. Currently, ANP is administered for treatment of HF by continuous intravenous infusion due to short half-life, the main limiting factor for its chronic use. Recently studies have defined a metabolic role of ANP beyond its blood pressure-lowering, natriuretic- and aldosterone-inhibiting properties, such that the ANP gene polymorphism rs5068 is associated with a low cardiovascular risk profile with protection from metabolic syndrome. Further physiological studies established that the gut peptide Glucagon-like Protein 1 (GLP-1) can stimulate the release of ANP from the atria also resulting in cardiorenal protection. Based upon these cardiorenal, humoral and metabolic properties of ANP, we engineered Mutant ANP (MANP) which represents a new and novel ANP-based peptide therapeutic consisting of 40 amino acids where the unique long C-terminus confers to the peptide a greater resistance to degradation than its native form. Indeed, in vitro studies demonstrated fewer sites for degradation and a greater cGMP production than ANP. In vivo studies showed sustained cardiorenal actions with enhanced vasorelaxation not only in normal canines but also in experimental acute hypertension and in hypertensive acute heart failure. In summary, for these reasons, MANP represents a new therapeutic agent for the treatment of chronic and resistant hypertension that is now entering human clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84956840460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956840460&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84956840460

SN - 9781633210837

SN - 9781633210806

SP - 77

EP - 100

BT - Natriuretic Peptides: Physiology, Molecular Biology, and Clinical Implications

PB - Nova Science Publishers, Inc.

ER -